A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ENV-501 in Patients With HER3-Expressing Solid Tumors (clinicaltrials.gov) - May 5, 2025 - P1/2 | N=180 | Recruiting | Sponsor: Endeavor Biomedicines, Inc.
New P1/2 trial • Breast Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor
|